小干扰RNA降脂药物药学专家共识
Pharmacy expert consensus on small interfering RNA lipid-lowering drugs
国家老年医学中心 中国医药教育协会老年药学专业委员会 中国药学会医院药学专业委员会 胡欣 1金鹏飞1
作者信息
摘要
小干扰RNA(small interfering RNA,siRNA)降脂药是一类新型降脂药物.目前,针对该类药物的循证证据和实践经验较少.为加强医务工作者对该类药物的认识、规范临床合理应用,由北京医院牵头,国家老年医学中心、中国医药教育协会老年药学专业委员会联合中国药学会医院药学专业委员会组织相关临床医学、药学和循证专家,基于循证证据和临床实践、采用德尔菲法经过3轮专家意见收集和充分研讨拟定本共识.共识介绍了 siRNA降脂药物的作用机制,并以已获批的药物英克司兰为例,就其临床证据、药物安全性等进行了阐述,以期为siRNA降脂药物的临床规范应用提供参考.
Abstract
Small interfering RNA(siRNA)lipid-lowering drugs are a new class of lipid-lowering agents.At present,there is little evidence-based evidence and practical experience for this class of drugs.In order to strengthen the awareness of medical work-ers and standardize the rational use of such drugs in clinical practice,led by the Beijing Hospital,the National Center for Geriat-rics,Geriatric Pharmacy Professional Committee of Chinese Medical Education Association and Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association organized relevant clinical medicine,pharmacy and evidence-based experts.Based on the evidence-based evidence and clinical practice,Delphi method was used to collect expert opinions,and fully discus-sion was performed through three rounds of expert consultation.The consensus introduced the mechanism of siRNA lipid-lowering drugs,and taking the marketed drug inclisiran as an example,the clinical evidence and drug safety were described,in order to provide reference for the standardized clinical application of siRNA lipid-lowering drugs.
关键词
小干扰RNA/动脉粥样硬化性心血管疾病/低密度脂蛋白胆固醇/英克司兰/专家共识Key words
small interfering RNA/atherosclerotic cardiovascular disease/low density lipoprotein cholesterin/inclisiran/expert consensus引用本文复制引用
基金项目
国家重点研发计划(2020YFC2008300)
国家重点研发计划(2020YFC2008305)
出版年
2024
NETL
NSTL
维普
万方数据